Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m. PST, to discuss the results of Rigel's Phase 2 clinical trial of R788, an oral Syk kinase inhibitor, in patients with B-cell non-Hodgkin's lymphomas.

Conference Call and Webcast Information

To access the live call, please dial 800-561-2693 (domestic) or 617-614-3523 (international) 10 minutes prior to the start time and use the passcode 36883961. A replay of the call will be available, in webcast and podcast formats, at approximately 6:00 p.m. PST on December 7, 2008 through December 14, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 47095093. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

In addition, Rigel will be participating in a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting in San Francisco, California from December 6-9, 2008.

ASH Presentation Details

Plenary session: Sunday, December 7, 2008 - 2:40 p.m. PST

Title: 3 - Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphoctytic Leukemia (SLL/CLL)

Location: Halls B and C (Moscone Center)

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

     Contact: Raul Rodriguez
     Phone: 650.624.1302
     Email: invrel@rigel.com

     Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
     Phone: 650.430.3777
     Email: susan@alchemyemail.com

'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Host Update Conference Call
4. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
5. Rigel to Present at BIO CEO & Investor Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel to Present Research Programs at Scientific Conferences
8. Rigel to Present at BIO Investor Forum 2007
9. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
10. Medarex to Present at the RBC Capital Markets Healthcare Conference
11. Bionovo to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):